Burning Rock Biotech (Burning Rock Biotech) FCF Margin % : -13.23% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Burning Rock Biotech's Free Cash Flow for the three months ended in Dec. 2023 was $-2.24 Mil. Burning Rock Biotech's Revenue for the three months ended in Dec. 2023 was $16.96 Mil. Therefore, Burning Rock Biotech's FCF Margin % for the quarter that ended in Dec. 2023 was -13.23%.

As of today, Burning Rock Biotech's current FCF Yield % is -43.86%.

The historical rank and industry rank for Burning Rock Biotech's FCF Margin % or its related term are showing as below:

BNR' s FCF Margin % Range Over the Past 10 Years
Min: -140.98 Med: -83.06 Max: -35.61
Current: -47.94

During the past 7 years, the highest FCF Margin % of Burning Rock Biotech was -35.61%. The lowest was -140.98%. And the median was -83.06%.

BNR's FCF Margin % is ranked worse than
69.37% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.09 vs BNR: -47.94

Burning Rock Biotech FCF Margin % Historical Data

The historical data trend for Burning Rock Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech FCF Margin % Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-71.73

-35.61

-136.13

-93.62

-49.34

Burning Rock Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-47.60	-79.39	-54.15	-37.17	-13.23

Competitive Comparison of Burning Rock Biotech's FCF Margin %

For the Diagnostics & Research subindustry, Burning Rock Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's FCF Margin % falls into.

Burning Rock Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Burning Rock Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-37.137	/	75.269
	=	-49.34 %

Burning Rock Biotech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.243	/	16.958
	=	-13.23 %

Burning Rock Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BNR:UK 6BUA:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.